Abstract
Review of current data on gemcitabine (Gemzar®) in non-small cell lung cancer
The efficacy of gemcitabine in advanced non-small cell lung cancer (NSCLC) has been established for several years. Gemcitabine can be used as monotherapy, particularly for elderly patients, or in association with cisplatin. The combination of cisplatin plus gemcitabine is a standard regimen in first-line chemotherapy for advanced NSCLC. During the 10th World Conference on Lung Cancer in Vancouver, some 80 abstracts relating to gemcitabine were presented, and there was a symposium on ‘The Present and Future Treatment of Thoracic Cancer’. One of the most interesting presentations was a meta-analysis comparing overall survival and progression-free survival using gemcitabine plus a platinum compound with other platinum-based comparators. This meta-analysis shows a significant benefit in favor of the gemcitabine-platinum combination in terms of overall survival and progression-free survival. Carboplatin can be substituted for cisplatin plus gemcitabine with a significant improvement in patient tolerability and without a significant loss of efficacy. This regimen can be particularly useful for elderly patients with a good performance status. In a French phase III randomized study, the combination of gemcitabine plus docetaxel was shown to be not only as effective as the cisplatin-vinorelbine doublet in terms of survival, but also less toxic. Further studies are necessary to assess the safety and efficacy profiles of gemcitabine in concurrent chemoradiation for stage IIIB NSCLC.
Résumé
La gemcitabine est un nouvel anticancéreux appartenant á la famille des antimétabolites. Son efficacité dans les cancers bronchiques á petites cellules (CBNPC) avancés est démontrée depuis plusieurs années. L’association gemcitabine—cisplatine est devenue une des chimiothérapies de référence dans le traitement de premiére ligne des CBNPC. Le 10ème Congrés Mondial sur le Cancer du Poumon a été l’occasion de confirmer la place de la gemcitabine dans la stratégie thérapeutique des CBNPC. La méta-analyse des essais randomisés comparant les associations gemcitabine—platine et les chimiothérapies á base de platine montre un bénéfice significatif en termes de survie sans progression et de survie globale en faveur des schémas gemcitabine—platine. L’association gemcitabine—carboplatine apparaŷt aussi efficace que le schéma gemcitabine—cisplatine. L’étude française confirme l’intérêt de l’association gemcitabine—docétaxel en traitement de premiére ligne des CBNPC avancés.
Similar content being viewed by others
References
Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535–40
Gatzmeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter extended phase II study Eur J Cancer 1996; 32A (Pt 2): 243–8
Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin vs cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122–30
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92–8
Le Chevalier T, Brown A, Fitzgerald P, et al. Gemcitabine in the treatment of advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2003; 41(Suppl. 2): 0–223
Barradas PS, Melo MJ, Cristovao MM, et al. Gemcitabine (G) or Vinorelbine (V) ? What’s the best drug in combination with platinum derivative for the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC) ? A 6-year retrospective study. Lung Cancer 2003: 41(Suppl. 2): S224
Paccagnella A, Favaretto A, Oniga F, et al. Paclitaxel/carboplatin (PC) vs paclitaxel/carboplatin/gemcitabine (PCG) in advanced NSCLC: preliminary results of an ongoing phase II–III multicentric study. Lung Cancer 2003; 41(Suppl. 2): S30
Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage MB and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41: 321–31
Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002; 21: 1162
Rudd RM, Gower NH, James LE, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 1164
Georgoulias V, Samonis G, Papadakis E, et al. Comparison of docetaxel/ cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 2001; 34(Suppl. 4): S47–51
Pujol JL, Breton JL, Riviere A, et al. Gemcitabine-docetaxel (GD) versus vinorelbine-cisplatin (VC) in advanced non-small cell lung cancer (NSCLC). A phase III study. Lung Cancer 2003; 41(Suppl. 2): S65
Cortesi E, Trodella L, Neli F, et al. Induction chemotherapy (CT) with gemcitabine (G), paclitaxel (T) and cisplatin (P) and subsequent radiotherapy (TRT) with concomitant G for stage IIIB non-small cell lung cancer (NSCLC): results of a multicenter phase II study. Lung Cancer 2003; 41(Suppl. 2): S151
Krzakowski M, Wenczl M, Brodowicz T, et al. Gemcitabine and Cisplatin (GC) +/− subsequent maintenance therapy with single agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). Lung Cancer 2003; 41(Suppl. 2): S29
Lilenbaum R, Bonomi P, Socinski MA. Phase II randomized trial of irinotecan/ docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib in second-line non small cell lung cancer (NSCLC) — preliminary results. Lung Cancer 2003; 41(Suppl. 2): S6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fournel, P. Actualités sur la Gemcitabine (Gemzar®) dans le Cancer Bronchique non à Petites Cellules. Am J Cancer 3 (Suppl 1), 9–12 (2004). https://doi.org/10.2165/00024669-200403991-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200403991-00003